WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H592076
CAS#: 514-10-3
Description: 2-ODA inhibitor of Plasmodium infections.
Hodoodo Cat#: H592076
Name: 2-ODA
CAS#: 514-10-3
Chemical Formula: C18H32O2
Exact Mass: 280.24
Molecular Weight: 280.450
Elemental Analysis: C, 77.09; H, 11.50; O, 11.41
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: 2-ODA
IUPAC/Chemical Name: 2-Octadecynoic Acid
InChi Key: WEAGGGHXTMXZQA-UHFFFAOYSA-N
InChi Code: InChI=1S/C18H32O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20/h2-15H2,1H3,(H,19,20)
SMILES Code: CCCCCCCCCCCCCCCC#CC(O)=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.03.00
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 280.45 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Carballeira NM, Bwalya AG, Itoe MA, Andricopulo AD, Cordero-Maldonado ML, Kaiser M, Mota MM, Crawford AD, Guido RV, Tasdemir D. 2-Octadecynoic acid as a dual life stage inhibitor of Plasmodium infections and plasmodial FAS-II enzymes. Bioorg Med Chem Lett. 2014 Sep 1;24(17):4151-7. doi: 10.1016/j.bmcl.2014.07.050. Epub 2014 Jul 24. PubMed PMID: 25103602; PubMed Central PMCID: PMC4146677.
2: Yuasa J, Mukai R, Hasegawa Y, Kawai T. Ratiometric luminescence thermometry based on crystal-field alternation at the extremely narrow ⁵D₀ → ⁷F₂ transition band of europium(III). Chem Commun (Camb). 2014 Jul 28;50(59):7937-40. doi: 10.1039/c4cc00704b. PubMed PMID: 24686443.
3: Carballeira NM. Recent developments in the antiprotozoal and anticancer activities of the 2-alkynoic fatty acids. Chem Phys Lipids. 2013 Jul-Aug;172-173:58-66. doi: 10.1016/j.chemphyslip.2013.05.002. Epub 2013 May 28. Review. PubMed PMID: 23727443; PubMed Central PMCID: PMC4110683.
4: Jiao C, Li F, Zhang J, Li Z, Wang S, Wang Z, Yu H, Li Z, Liu S, Wang Z, Jiang X, Sun L, Xu F. Syntheses, structures and chemical sensing properties of three complexes with mixed ligands of carboxylate and bipyridine. Dalton Trans. 2013 Feb 7;42(5):1346-51. doi: 10.1039/c2dt31867a. Epub 2012 Nov 22. PubMed PMID: 23172111.
5: Siddiqi ZA, Sharma PK, Shahid M, Khalid M, Anjuli, Siddique A, Kumar S. Superoxide scavenging and antimicrobial activities of novel transition metal complexes of oxydiacetate dianion as primary ligand: spectral characterization, cyclic voltammetric investigations and crystal structure. Eur J Med Chem. 2012 Nov;57:102-11. doi: 10.1016/j.ejmech.2012.08.043. Epub 2012 Sep 7. PubMed PMID: 23047227.
6: Carballeira NM, Cartagena M, Sanabria D, Tasdemir D, Prada CF, Reguera RM, Balaña-Fouce R. 2-Alkynoic fatty acids inhibit topoisomerase IB from Leishmania donovani. Bioorg Med Chem Lett. 2012 Oct 1;22(19):6185-9. doi: 10.1016/j.bmcl.2012.08.019. Epub 2012 Aug 10. PubMed PMID: 22932312; PubMed Central PMCID: PMC3483883.
7: Zhou Q, Yang F, Liu D, Peng Y, Li G, Shi Z, Feng S. Synthesis, structures, and magnetic properties of three fluoride-bridged lanthanide compounds: effect of bridging fluoride ions on magnetic behaviors. Inorg Chem. 2012 Jul 16;51(14):7529-36. doi: 10.1021/ic300125y. Epub 2012 Jul 2. PubMed PMID: 22747520.
8: León IE, Etcheverry SB, Parajón-Costa BS, Baran EJ. Spectroscopic characterization of an oxovanadium(IV) complex of oxodiacetic acid and o-phenanthroline. Bioactivity on osteoblast-like cells in culture. Biol Trace Elem Res. 2012 Jun;147(1-3):403-7. doi: 10.1007/s12011-012-9322-z. Epub 2012 Jan 13. PubMed PMID: 22246791.
9: Lennartson A, Håkansson M. Hydrogen-bonded network structures in dipyridinium, bis(2-methylpyridinium), bis(3-methylpyridinium) and bis(4-methylpyridinium) dioxidobis(oxydiacetato)uranate(VI). Acta Crystallogr C. 2010 Mar;66(Pt 3):m69-74. doi: 10.1107/S0108270109053839. Epub 2010 Feb 3. PubMed PMID: 20203398; PubMed Central PMCID: PMC2855580.
10: Tian G, Rao L, Oliver A. Symmetry and optical spectra: a "silent" 1 : 2 Np(V)-oxydiacetate complex. Chem Commun (Camb). 2007 Oct 28;(40):4119-21. Epub 2007 Aug 6. PubMed PMID: 17925948.
11: Di Nicola C, Galindo A, Hanna JV, Marchetti F, Pettinari C, Pettinari R, Rivarola E, Skelton BW, White AH. Synthesis and spectroscopic and X-ray structural characterization of R2Sn(IV)-oxydiacetate and -iminodiacetate complexes. Inorg Chem. 2005 May 2;44(9):3094-102. PubMed PMID: 15847414.
12: Rizzi AC, Calvo R, Baggio R, Garland MT, Peña O, Perec M. Carboxylate-bridged copper(II)-lanthanide(III) complexes [(Cu(3)Ln(2)(oda)(6)(H(2)O)(6)).12H(2)O](n)(Ln = Dy, Ho, Er, Y; oda = oxydiacetate). Inorg Chem. 2002 Oct 21;41(21):5609-14. PubMed PMID: 12377061.
